The Latest Cardiac and Vascular News
Results with next-generation cardiac myosin inhibitor suggest a potentially disease-modifying therapy in non-obstructive hypertrophic cardiomyopathy HRS/BHB-1893 treatment resulted in rapid and sustained reductions in key biomarkers, structural remodeling and meaningful improvements in…
Leadership brings experience in company building, advancing late-stage clinical programs, and deep understanding of cardiovascular drug development Company intends to rapidly advance BHB-1893 into late-stage clinical development Board to include Chris Viehbacher as Chair, with investor…
Collaboration highlights Hengrui Pharma’s successful use of the NewCo model to achieve another out-licensing deal Agreement grants Braveheart Bio exclusive global rights to develop, manufacture and commercialize HRS-1893 outside of Mainland China, the Hong Kong SAR, the Macao SAR and…
